Altre lingue Can-Fite BioPharma Ltd.

Azioni

CANF

IL0010944739

Tempo differito TEL AVIV STOCK EXCHANGE Altri mercati azionari 14:36:13 30/06/2024			Variaz. 5gg	Var. 1 gen.
3,4 ^ILa	+3,03%		+3,03%	+30,77%

28/06	Can-Fite BioPharma Ltd. annuncia i risultati positivi dello studio clinico sull'osteoartrite nei cani riportato da Vetbiolix	CI
24/06	Can-Fite annuncia scoperte rivoluzionarie che dimostrano il meccanismo dell'effetto antitumorale e protettivo di Namodenoson nel fegato	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Can Fite BioPharma : Other Report or Announcement	28/06
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix	28/06
Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix	28/06
Can Fite BioPharma : Other Report or Announcement	26/06
Can Fite BioPharma : Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	24/06
Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver	24/06
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver	24/06
Can Fite BioPharma : Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10/06
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10/06
Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study	10/06
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study	05/06
Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study	05/06
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases	29/05
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024	27/05
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6	23/05
Can Fite BioPharma : Immediate Report of Meeting	22/05
Can Fite BioPharma : NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	22/05
Can Fite BioPharma : Immediate Report	13/05
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	13/05
CAN-FITE, FDA GRANTS IND CLEARANCE FOR NAMODENOSON TO TREAT MASH PATIENTS IN A PHASE IIB STUDY	10/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Can-Fite BioPharma Ltd.

Azioni

CANF

IL0010944739

Altre lingue

Filtri